1. P223 Degree of Histological Activity is not Associated with Vedolizumab Therapy Outcome in Ulcerative Colitis. (27th May 2021) Authors: Doherty, J; Brennan, S; Dinneen, K; Muldoon, C; Mc Kiernan, S; Dunne, C; Mac Carthy, F; Hartery, K; Ciara, R; Kevans, D Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S276 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P408 Anti-Drug Antibodies Detected in the Presence of Adequate Infliximab Drug Levels In IBD Patients in Clinical Remission have Limited Clinical Significance. (27th May 2021) Authors: Doherty, J; Varley, R; Healy, M; Dunne, C; Mac Carthy, F; McKiernan, S; Hartery, K; Kevans, D Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S415 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P449 Cost Effectiveness of a Proactive Therapeutic Drug Monitoring Strategy in Patients with Inflammatory Bowel Disease Receiving Infliximab. (27th May 2021) Authors: Doherty, J; Varley, R; Healy, M; Dunne, C; Mac Carthy, F; Mc Kiernan, S; Hartery, K; Kevans, D Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S445 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗